Lupin Achieves Significant Milestone with China Approval of New Oseltamivir Oral Suspension

Expanding Horizons: Lupin’s Entry into China

Lupin Limited, a global leader in the pharmaceutical industry, has taken a significant step forward by gaining approval from the National Medical Products Administration of China for its oral suspension of oseltamivir phosphate. This announcement marks the first introduction of Lupin’s products into the Chinese market in collaboration with Yabao Pharmaceuticals, a prominent player in pediatric medications. The approval represents a major milestone in Lupin's strategic expansion efforts in one of the world's largest pharmaceutical markets.

The oral suspension of oseltamivir phosphate, formulated at 6 mg/mL, is specifically designed for pediatric use, allowing easier administration for younger patients suffering from influenza. The medication is crucial for treating influenza A and B in children aged two weeks and older, and for prevention among those aged one year and above. By offering this solution, Lupin aims to enhance accessibility to essential medicines, particularly for vulnerable pediatric populations.

Fabrice Egros, President of Business Development at Lupin, expressed excitement over this development, noting, "We are thrilled to have received approval for the oseltamivir oral suspension in China. This is a strategic step in our entry into one of the largest pharmaceutical markets globally. This authorization reflects our mutual commitment to expand access to high-quality and affordable therapies, especially in pediatric care. We look forward to enhancing our presence in this market through our partnership."

Additionally, Wei Ren, President of Yabao, remarked on the importance of the new approval, emphasizing the strong partnership with Lupin and their shared goal of delivering quality pediatric medications. He stated, "We are pleased to announce the official approval for oseltamivir oral suspension in China, marking a key milestone in our partnership with Lupin. It reinforces Yabao’s commitment to quality pediatric medications and highlights our close collaboration. We will continue to develop our R&D portfolio for chronic conditions in both pediatric and adult populations to mutually advance our businesses."

About Lupin Limited

Founded and headquartered in Mumbai, India, Lupin Limited has established a robust presence in over 100 markets worldwide. The company specializes in various pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients (APIs). Recognized for its commitment to quality, Lupin maintains a strong foothold in India and the United States, with therapeutic areas spanning respiratory, cardiovascular, diabetes management, anti-infectives, gastrointestinal, CNS, and women’s health. With a dedicated workforce of over 24,000 employees across seven research centers and 15 state-of-the-art manufacturing sites globally, Lupin’s mission focuses on improving patient health outcomes through a range of solutions, including Lupin Diagnostics and Lupin Digital Health.

For more information, visit www.lupin.com and connect with us on LinkedIn.

About Yabao Pharmaceuticals

Yabao Pharmaceutical Co., a leading Chinese pharmaceutical enterprise listed on the Shanghai Stock Exchange, specializes in fully integrated research, manufacturing, and marketing of pharmaceutical products. Yabao is dedicated to innovating pharmaceutical products while maintaining its core operations in modern traditional Chinese medicines and generic chemicals. With robust clinical and regulatory capabilities, alongside strong formulation and manufacturing expertise, Yabao is committed to meeting the highest standards of quality and innovation in healthcare.

Explore more at www.yabao.com.cn.